Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.

Drug selectivity is one of the most critical improvement steps in drug development. The 5-hydroxytryptamine 2 (5-HT₂) receptor has 3 subtypes that exhibit different pharmacological functions. Because of their high amino acid sequence similarity, designing small molecules that selectively activate only 1 receptor among the 3 subtypes is difficult. We performed homology modeling of the 5-HT₂ receptor subtypes using the β₂-adrenergic receptor as a template to identify differences in active sites that may influence 5-HT₂ receptor agonist selectivity. A subset of selective 5-HT₂ agonists was docked into the modeled protein structures to investigate their interactions with each receptor. Subtype-specific active site residues at positions xl2.54, 5.39, and 5.46 interacted differently with each ligand. Molecular dynamics simulations revealed that position 5.46 of the 5-HT(2A) receptor interacted more favorably with selective 5-HT(2A) agonists than with selective 5-HT(2B) agonists. These computationally obtained insights provided clues to improving agonist selectivity for specific pharmacological action at 5-HT₂ receptors.

[1]  M. Isaac Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. , 2005, Current topics in medicinal chemistry.

[2]  J. Thompson,et al.  Using CLUSTAL for multiple sequence alignments. , 1996, Methods in enzymology.

[3]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[4]  Ruben Abagyan,et al.  Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..

[5]  Brian M. Smith,et al.  Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. , 2008, Journal of medicinal chemistry.

[6]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[7]  B. Roth Multiple serotonin receptors: clinical and experimental aspects. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[8]  G. Kennett,et al.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[10]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[11]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[12]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[13]  B. Kobilka,et al.  New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.

[14]  P. Delgado,et al.  Hallucinogens, serotonin and obsessive-compulsive disorder. , 1998, Journal of psychoactive drugs.

[15]  D. Middlemiss,et al.  Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.

[16]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[17]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[18]  M. Dallman,et al.  Compulsive behavior in the 5-HT2C receptor knockout mouse , 2003, Physiology & Behavior.

[19]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[20]  G. Kennett,et al.  Indoline derivatives as 5-HT(2C) receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.

[21]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[22]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[23]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[24]  Marta Filizola,et al.  Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.

[25]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[26]  B. Roth,et al.  The expanded biology of serotonin. , 2009, Annual review of medicine.

[27]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[28]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[29]  R. Glennon,et al.  Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis , 1989, Psychopharmacology.

[30]  G. Kennett,et al.  Evidence that hypophagia induced bymCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors , 2006, Psychopharmacology.

[31]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[32]  G. Martin,et al.  5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome , 1997, Neuropharmacology.

[33]  M. Millan,et al.  5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. , 1997, European journal of pharmacology.

[34]  L. Parsons,et al.  Enhanced Locomotor, Reinforcing, and Neurochemical Effects of Cocaine in Serotonin 5-Hydroxytryptamine 2C Receptor Mutant Mice , 2002, The Journal of Neuroscience.

[35]  T. Blackburn,et al.  BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.

[36]  B. Roth Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[37]  A. Brown,et al.  SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.

[38]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[39]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[40]  J. Ponder,et al.  Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.

[41]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[42]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[43]  N. Weissman Appetite suppressant valvulopathy : A review of current data , 1999 .

[44]  R. Glennon,et al.  Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. , 1990, The Journal of pharmacology and experimental therapeutics.

[45]  J. Vry,et al.  Effects of selected serotonin 5-HT1 and 5-HT2 receptor agonists on feeding behavior: possible mechanisms of action , 2000, Neuroscience & Biobehavioral Reviews.

[46]  H Weinstein,et al.  Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.

[47]  Ruben Abagyan,et al.  Structure based prediction of subtype-selectivity for adenosine receptor antagonists , 2011, Neuropharmacology.

[48]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[49]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[50]  K. Miller Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. , 2005, Molecular interventions.

[51]  R. Glennon,et al.  Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens , 2004, Psychopharmacology.

[52]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[53]  G. Aghajanian,et al.  LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. , 1996, The Journal of pharmacology and experimental therapeutics.

[54]  R. Glennon,et al.  Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.

[55]  B. Roth,et al.  Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.

[56]  B. Roth,et al.  Insights into the structure and function of 5-HT2 familyserotonin receptors reveal novel strategies for therapeutic target development , 2001, Expert opinion on therapeutic targets.

[57]  Philippe Manivet,et al.  The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. , 2002, The Journal of biological chemistry.

[58]  F E Cohen,et al.  Novel method for the rapid evaluation of packing in protein structures. , 1990, Journal of molecular biology.

[59]  A. Sleight,et al.  Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. , 1997, Journal of medicinal chemistry.

[60]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[61]  Philippe Manivet,et al.  Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. , 2003, Life sciences.

[62]  D. Baker,et al.  Clustering of low-energy conformations near the native structures of small proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.